Abstracts tagged "Disease Activity"

Abstract Number: 1409 • 2016 ACR/ARHP Annual Meeting
Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007
Marieke J. de Jonge¹, Laura W.M. Boerboom¹, Anita M.P. Huis¹, Julia M. Weijers¹, Mart A.F.J. van de Laar², Marlies E.J.L. Hulscher¹ and Piet L.C.M. van Riel^1,3, ¹Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, ²University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ³Bernhoven, Department of Rheumatology, Uden, Netherlands
Background/Purpose: International guidelines and studies recommend rheumatologists to use validated measures to monitor disease activity, such as the Disease Activity Score of 28 joints (DAS28).…
Abstract Number: 1677 • 2016 ACR/ARHP Annual Meeting
Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis
Andreas Kerschbaumer^1,2, Karl Fenzl², Michael Weber³, Johannes Resch⁴, Martin Kasper⁴, Daniel Aletaha⁵ and Ludwig Erlacher^4,6, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Institute for Autoimmune Diseases and Rheumatology, Karl Landsteiner Institute, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴2nd Medical Department, Department for Rheumatology, Osteology and Geriatric medicine, Sozialmedizinisches Zentrum Sued, Vienna, Austria, ⁵Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria, ⁶Karl Landsteiner Institute, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in a subgroup of patients suffering from psoriasis. Assessment of PsA disease activity currently mainly…
Abstract Number: 1992 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Is an Independent Risk Factor for Increased Insulin Resistance and Impaired Beta-Cell Function: Impact of Disease Activity
Gorica Ristic¹, Vesna Subota², Dejana Stanisavljevic³, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in pts with rheumatoid arthritis (RA). The aim of our study was to investigate…
Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Josef Smolen¹, Yihan Li², Iain Sainsbury², Stefan Florentinus², Kershnie Rambalee² and GR Burmester³, ¹Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…
Abstract Number: 2736 • 2016 ACR/ARHP Annual Meeting
Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Marina N. Magrey¹, Sherilyn Diomampo² and Muhammad Asim Khan³, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Cleveland, OH, ³Medicine/ Rheumatology, Case Western Reserve Univ, Cleveland, OH
Background/Purpose: Concomitant fibromyalgia syndrome (FMS) is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management. BASDAI, a disease activity…
Abstract Number: 2965 • 2016 ACR/ARHP Annual Meeting
Late-Onset Relapse in Patients with Systemic Vasculitis
Rennie L. Rhee¹, Natasha Dehghan², Antoine G. Sreih³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Jeffrey Krischer⁹, Carol A. Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Ulrich Specks¹⁶, Steven R. Ytterberg¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹University of South Florida, Tampa, FL, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Medicine, Johns Hopkins University, Baltimore, MD, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Little is known about the incidence of late-onset relapse in systemic vasculitis. This study examined the incidence of relapse < 2 years and ≥ 2…
Abstract Number: 450 • 2016 ACR/ARHP Annual Meeting
Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Susan J. Bartlett^1,2, Skye Barbic³, Vivian P. Bykerk⁴, Bruno Fautrel⁵, Francis Guillemin⁶, A den Broeder⁷, R Alten⁸, Robin Christensen⁹, Ernest H. Choy¹⁰, Daniel E. Furst¹¹, Sarah Hewlett¹², Amye L. Leong¹³, Lyn March¹⁴, Thasia G Woodworth¹⁵, Clifton Bingham III¹⁶ and OMERACT Flare Group and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of British Columbia, Vancouver, BC, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁶University of Lorraine, Nancy, France, ⁷Rheumatology, Maartenskliniek, Nijmegen, Netherlands, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany, ⁹The Parker instutute, RC, Copenhagen, Denmark, ¹⁰Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ¹¹University of California, Los Angeles, Los Angeles, CA, ¹²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹³Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹⁴Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁵Leading Edge Clinical Research, Stuart, FL, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: OMERACT Filter 2.0 encourages use of robust methods to develop new measures. Instrument results also should be highly relevant, easily scored and interpreted, and…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Frank Behrens¹, Tanja Rossmanith², Michaela Koehm³, Rieke Alten⁴, Martin Aringer⁵, GR Burmester⁶, Eugen Feist⁷, Klaus Krüger⁸, Ulf Müller-Ladner⁹, Andrea Rubbert-Roth¹⁰, Siegfried Wassenberg¹¹, Hans-Peter Tony¹², Herbert Kellner¹³, Marina Backhaus¹⁴ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ⁴Schlosspark-Klinik University Medicine, Berlin, Germany, ⁵Abteilung für Rheumatologie, Dresden, Germany, ⁶Charité – University Medicine Berlin, Berlin, Germany, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Praxiszentrum St. Bonifatius, München, Germany, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰Division Rheuamatology, University Köln, Köln, Germany, ¹¹Rheumazentrum, Ratingen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Rheumatology Patient Care, Munchen, Germany, ¹⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…
Abstract Number: 1415 • 2016 ACR/ARHP Annual Meeting
Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting
Irene Lazarus¹, Salahuddin Kazi², Alok Dwivedi³, Christopher Dodoo⁴ and Kanchan Pema⁵, ¹Internal Medicine, Texas Tech University Health Science Center, El Paso, TX, ²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Biomedical Sciences Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Internal Medicine/Rheumatology, Texas Tech University Health Science Center, El Paso, TX
Background/Purpose: Since 2008 the Center for Medicare and Medicaid Services (CMS) has been in the process of changing patient care to quality-valued healthcare. In order…
Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Renganayaki Pandurengan², Christopher T. Ritchlin⁴, Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…
Abstract Number: 1995 • 2016 ACR/ARHP Annual Meeting
Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Shafay Raheel¹, Cynthia S. Crowson², Eric L. Matteson¹ and Elena Myasoedova¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Smoking is well recognized as a risk factor for rheumatoid arthritis (RA), and determinant of RA disease activity, severity, response to therapy, and possibly…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 2991 • 2016 ACR/ARHP Annual Meeting
A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population
Michelle Petri¹, Kenneth C. Kalunian², Murray Urowitz³, David A. Isenberg⁴, Richard Furie⁵, MaryAnn Morgan-Cox⁶, Maria Silk⁷, Ernst R. Dow⁸, Richard Higgs⁷, Steven Watts⁷ and Matthew D Linnik⁹, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁵North Shore University Hospital, Great Neck, NY, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Indianapolis, IN, ⁸Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁹Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Registration trials for SLE therapeutics require large numbers of patients with active disease, which in turn necessitates the trials be multinational with many participating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].